TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$69 Million

AVITA Medical

Follow-on Offering

Bookrunner, February 2021

AVITA Medical

AVITA Medical, Inc. is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. Avita’s patented and proprietary platform technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. Avita’s first FDA approved product, the RECELL System, produces Spray-on Skin cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required.